# Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa

> **NCT04982432** · PHASE2 · UNKNOWN · sponsor: **Gregor Jemec** · enrollment: 24 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Orismilast

## Key facts

- **NCT ID:** NCT04982432
- **Lead sponsor:** Gregor Jemec
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2021-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982432, "Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04982432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*